From process to progress—2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. Issue 6 (25th March 2019)

• Record Type: Journal Article
• Authors: Ferner, Rosalie E.; Bakker, Annette; Elgersma, Ype; Evans, D. Gareth R.; Giovannini, Marco; Legius, Eric; Lloyd, Alison; Messiaen, Ludwine M.; Plotkin, Scott; Reilly, Karlyne M.; Schindeler, Aaron; Smith, Miriam J.; Ullrich, Nicole J.; Widemann, Brigitte; Sherman, Larry S.
• Is Part Of: American journal of medical genetics. Volume 179:Issue 6(2019)
• Page Start: 1098
• Page End: 1106
• Publication Date: 2019-03-25
• Subjects: neurofibromatosis 1 -- neurofibromatosis 2 -- schwannomatosis; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.61112
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract : The neurofibromatoses are inherited, tumor suppressor disorders that are characterized by multiple, benign peripheral nerve sheath tumors and other nervous system tumors. Each disease is associated with a distinct genetic mutation and with a different pathogenesis and clinical course. Neurofibromatosis 1 (NF1) is common and epitomized by multiple neurofibromas with widespread complications. NF2 and schwannomatosis are rare diseases that are typified by multiple schwannomas that are particularly painful in people with schwannomatosis. Since 1985, the Children's Tumor Foundation (formerly the National Neurofibromatosis Foundation) has hosted an international Neurofibromatosis Conference, bringing together international participants who are focused on NF research and clinical care. The 2017 Conference, held in Washington, DC, was among the largest gatherings of NF researchers to date and included presentations from clinicians and basic scientists, highlighting new data regarding the molecular and cellular mechanisms underlying each of these diseases as well as results from clinical studies and clinical trials. This article summarizes the findings presented at the meeting and represents the current state‐of‐the art for NF research.